BACKGROUND Cerebral amyloid angiopathy - related inflammation (CAA-ri) is an uncommon manifestation of CAA. METHODS Single-center, retrospective review of all charts with ICD-code I68.0 (CAA) from 2/2/2016-1/1/2020. RESULTS Of 152 CAA cases, 13 (8.6%) were consistent with CAA-ri. Corticosteroid-treatment led to short-term reduction in modified Rankin Scale scores (2.6 ± 1.4 vs. 1.6 ± 1.5; p = 0.01) and T2/FLAIR lesion volume (78.1 ± 52.2 cm3 vs. 30 ± 30.9 cm3, p < 0.01) as well as short-term improvement in post-treatment Clinical Global Impression - Global Change scores compared to pre-treatment scores (clinical: 6 ± 1 vs. 2.6 ± 1.3, p = 0.03; radiological: 4.6 ± 1.9 vs. 1.2 ± 0.4, p = 0.03). INTERPRETATION Corticosteroid-treatment leads to clinical and radiological short-term improvement (class IV evidence).

中文翻译：

---

皮质类固醇可短期改善脑淀粉样血管病相关炎症

背景脑淀粉样血管病相关炎症(CAA-ri)是CAA的罕见表现。方法 对 2/2/2016-1/1/2020 的 ICD 代码 I68.0 (CAA) 的所有图表进行单中心、回顾性审查。结果 在 152 例 CAA 病例中，13 例 (8.6%) 与 CAA-ri 一致。皮质类固醇治疗导致改良 Rankin 量表评分（2.6 ± 1.4 对 1.6 ± 1.5；p = 0.01）和 T2/FLAIR 病灶体积（78.1 ± 52.2 cm3 对 30 ± 30.9 cm3，p < 0.01）的短期降低以及治疗后临床总体印象的短期改善 - 与治疗前评分相比的总体变化评分（临床：6 ± 1 vs. 2.6 ± 1.3，p = 0.03；放射学：4.6 ± 1.9 vs. 1.2 ± 0.4 , p = 0.03)。解释 皮质类固醇治疗导致临床和放射学短期改善（IV 类证据）。